NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration ...

Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64 billion in aggregate option fees and milestones, as well as tiered ...

The collaboration follows a partnership between AbbVie and Neomorph in January 2025, focusing on the development of molecular glue degraders. The treatments are intended for use in oncology and ...

The announcement comes less than a month after AbbVie partnered with Neomorph to develop new drug candidates for multiple targets across oncology and immunology in a deal worth $1.64bn. The ...

AbbVie has partnered with Neomorph to develop molecular glue degraders, a new class of drugs targeting proteins involved in cancer and immune system disorders. This collaboration could lead to ...

AbbVie’s Option-to-License Deal With Neomorph AbbVie announced an option-to-license agreement with Neomorph to develop novel molecular glue degraders for multiple targets across oncology and ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $227.00. The company’s shares closed last ...

Neomorph Inc. has signed another billion-dollar deal to develop molecular glue degraders, this time with Abbvie Inc. It’s the third agreement in the past year the five-year-old company has signed with ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...